VACCINEX INC
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
VCNX$1.41-61.4%Stored close · as of Dec 17, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
Exhibits
INDEX TO EXHIBITS
| Exhibit No. | Description |
| 4.1 | Form of Pre-Funded Warrant (incorporated herein by reference from Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on February 7, 2024) |
| 4.2 | Form of Common Stock Warrant (incorporated herein by reference from Exhibit 4.2 to the Company’s Current Report on Form 8-K/A filed on February 8, 2024) |
| 4.3 | Form of Amendment and Restatement of the Vaccinex, Inc. Common Stock Purchase Warrant (February 2024, as amended March 2024) (incorporated herein by reference from Exhibit 4.3 to the Company's Quarterly Report on Form 10-Q filed on May 15, 2024) |
| 4.4 | Form of Amendment and Restatement of the Vaccinex, Inc. Common Stock Purchase Warrant (November 2023, as amended March 2024) (incorporated herein by reference from Exhibit 4.4 to the Company's Quarterly Report on Form 10-Q filed on May 15, 2024) |
| 4.5 | Form of Amendment and Restatement of the Vaccinex, Inc. Common Stock Purchase Warrant (October 2023, as amended March 2024) (incorporated herein by reference from Exhibit 4.5 to the Company's Quarterly Report on Form 10-Q filed on May 15, 2024) |
| 4.6 | Form of Common Stock Purchase Warrant for AGP Transactions, dated March 28, 2024 (incorporated herein by reference from Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on April 1, 2024) |
| 4.7 | Form of Common Stock Purchase Warrant for Private Placement, dated March 28, 2024 (incorporated herein by reference from Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on April 1, 2024) |
| 4.8 | Common Stock Purchase Warrant issued to Alzheimer’s Drug Discovery Foundation, dated March 29, 2024 (incorporated herein by reference from Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on April 1, 2024) |
| 10.1+ | First Amendment to the Vaccinex, Inc. 2018 Omnibus Incentive Plan (incorporated herein by reference from Appendix B to the Company’s Definitive Proxy Statement on Schedule 14A dated April 2, 2024). |
| 31.1* | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 31.2* | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1** | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents |
| 104 | The cover page for the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL and contained in Exhibit 101 |
- Filed herewith.
** Furnished herewith.
- Management contract.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.